Rigontec GmbH – A Dual Approach To Treat Cancer, Rigontec is a privately held biopharmaceutical company that develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases, synta pharmaceuticals.#Synta #pharmaceuticals


Posted On Mar 14 2018 by

synta pharmaceuticals

  • Synta pharmaceuticals

pathways in the innate immune system

to generate effective therapies

  • Synta pharmaceuticals

    pathways in the innate immune system

    to generate effective therapies

  • Synta pharmaceuticals

    pathways in the innate immune system

    to generate effective therapies

    Company

    Overview

    Harnessing one of the most essential pathways in the innate immune system to generate effective therapies

    Rigontec is the leader in RIG-I targeting therapeutics. Utilizing our proprietary RIG-I agonist platform, we harness one of the most essential pathways in the innate immune system to pioneer a novel immuno-oncology treatment approach.

    Rigontec’s proprietary agonists specifically activate RIG-I, inducing both immediate and long-term anti-tumor immunity and have proven substantial local and systemic tumor regression in several relevant in vivo models.

    In addition to malignant diseases, our innovative bifunctional RNA molecules can be developed for the treatment of infectious and inflammatory diseases.

    Company

    Investors Funding

    The company has raised €29.25 million in its recent Series A financing round. Rigontec is supported by a consortium of experienced life science investors including Wellington Partners, Boehringer Ingelheim Venture Fund, NRW.BANK, High-Tech Gründerfonds (HTGF), Forbion Capital Partners, Sunstone Capital and MP Healthcare Venture Management.

    All our Investors Funding

    Synta pharmaceuticals

    Synta pharmaceuticals

    Boehringer Ingelheim Venture Fund

    The Boehringer Ingelheim Venture Fund was formed in March 2010 to invest in biotechnology and start-up companies to help drive innovation in medical science.

    Synta pharmaceuticals

    Forbion Capital Partners

    Forbion Capital Partners is a dedicated Life Sciences venture capital firm with offices in Naarden, The Netherlands, Munich, Germany and representation in Boston, US.

    Synta pharmaceuticals

    High-Tech Gründerfonds (HTGF)

    High-Tech Gründerfonds invests in young, high potential high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping and to market launch.

    Synta pharmaceuticals

    MP Healthcare Venture Management, Inc.

    MP Healthcare Venture Management (MPH) is a Boston-based lifesciences venture capital firm that invests in innovative research-driven companies in the areas of biotechnology, therapeutics and vaccines.

    Synta pharmaceuticals

    NRW.BANK

    NRW.BANK is the development bank for the State of North Rhine-Westphalia. It supports its owner – the State of North Rhine-Westphalia – in fulfilling its tasks, especially in the fields of structural, economic, social and housing policy.

    Synta pharmaceuticals

    Sunstone Capital

    Sunstone Capital is an independent venture capital investor founded in 2007 by an international team of industry experts with combined entrepreneurial, operational and financial experience.

    Synta pharmaceuticals

    Wellington Partners

    Wellington Partners is one of the most successful pan-European venture capital firms.

    Management

    Synta pharmaceuticalsChristian Schetter, Ph.D. (CEO)

    Christian joined Rigontec from Neovii Biotech GmbH, previously Fresenius Biotech GmbH, where he was President and CEO from 2008 until 2014. During his tenure, one antibody product was brought to market and the indication for another product expanded. Dr. Schetter was instrumental in selling Fresenius Biotech to the Neopharm Group to form Neovii Biotech and positioning it as a successful standalone business.

    From 1998 to 2008, Christian was Senior Vice President, European Operations of Coley Pharmaceutical Group Inc., a pioneer in the development of immunostimulatory oligonucleotides, and served as Managing Director of Coley GmbH. He was part of the leadership team which built Coley Pharmaceuticals from inception through multiple financing rounds, a NASDAQ IPO and, following a number of significant pharma deals, to a trade sale to Pfizer in 2007.

    Christian received his undergraduate degree and PhD from the University of Cologne followed by a postdoctoral research in oncology and virology at the Scripps Research Institute in La Jolla, California and the Max Planck Institute in Martinsried, Germany. He is a member of the Executive Board of BIO Deutschland, the German industry association for biotech companies.

    Synta pharmaceuticalsAnne Burger (CFO)

    Anne has held the finance function for various companies in the life sciences and health care industry across Europe. Since 2002, she has been active in the industry and has been responsible for numerous companies and projects in the field of private placements, M A, corporate structuring and financial modeling.

    She is Managing Director of MedVenture GmbH, a Munich-based corporate finance and strategic advisory company focusing on the life sciences and health care industry.

    Anne holds a graduate degree in business administration (Ludwig-Maximilian-Universität Munich, Honors).


  • Last Updated on: March 14th, 2018 at 5:36 pm, by


    Written by admin


    Leave a Reply

    Your email address will not be published. Required fields are marked *